Symptom Clusters and Key Symptoms Among Midlife Perimenopausal and Postmenopausal Women With and Without Metabolic Syndrome.

Journal Article (Journal Article)

Background

Midlife perimenopausal and postmenopausal women with metabolic syndrome experience multiple symptoms concurrently.

Objective

The study objectives were to examine the relationship among symptoms through network visualization and identify and compare symptom clusters and key symptoms across symptom occurrence and symptom severity dimensions in midlife perimenopausal and postmenopausal women with and without metabolic syndrome.

Methods

Cross-sectional data from the Study of Women's Health Across the Nation (Visit 5) were used for analysis. A machine-learning-based network analysis and the Walktrap algorithm were used to fulfill the study objectives.

Results

The number and types of symptom clusters differed between the groups. Midlife perimenopausal and postmenopausal women with metabolic syndrome experienced the psychological/somatic/genital cluster (key symptom: frequent mood change), the sleep/urinary cluster (sleep disturbance), and the vasomotor cluster (cold sweat) in the symptom occurrence dimension and the psychological/somatic/sexual cluster (anxiety), the sleep/urinary cluster (sleep disturbance), and the vasomotor/genital cluster (night sweat) in the symptom severity dimension. In contrast, midlife perimenopausal and postmenopausal women without metabolic syndrome experienced the psychological cluster (anxiety), the sleep/somatic/genitourinary cluster (sleep disturbance), and the vasomotor cluster (night sweat) in the symptom occurrence dimension and the psychological/somatic cluster (anxiety), the sleep/urinary cluster (sleep disturbance), the vasomotor cluster (night sweat), and the sexual/genital cluster (vaginal dryness) in the symptom severity dimension.

Discussion

The study findings may serve as a knowledge basis for effective assessment and management of symptom clusters and key symptoms in clinical settings and provide directions for future development of targeted symptom management interventions.

Full Text

Duke Authors

Cited Authors

  • Min, SH; Yang, Q; Docherty, SL; Im, E-O; Hu, X

Published Date

  • July 2022

Published In

Volume / Issue

  • 71 / 4

Start / End Page

  • E28 - E38

PubMed ID

  • 35759720

Pubmed Central ID

  • PMC9237449

Electronic International Standard Serial Number (EISSN)

  • 1538-9847

International Standard Serial Number (ISSN)

  • 0029-6562

Digital Object Identifier (DOI)

  • 10.1097/nnr.0000000000000591

Language

  • eng